Palisade Bio Advances Clinical Trials for Crohn’s Disease Treatment
Patients dealing with fibrostenotic Crohn’s disease (FSCD) face a challenging health landscape, with limited treatment options available. Today, Palisade Bio, Inc. (Nasdaq: PALI) is making significant strides by recently obtaining a No Objection Letter from Health Canada for its pivotal Phase 1b trial involving PALI-2108, a unique drug designed to address this gap in care.
Understanding Fibrostenotic Crohn’s Disease
FSCD is a severe complication of Crohn’s disease that occurs in about half of those affected by this chronic condition. Conventional treatments, such as corticosteroids and surgery, primarily focus on symptom management without effectively addressing the underlying fibrotic process. This has left many patients frustrated with ongoing pain and recurring medical procedures. The urgency for new, effective therapies has never been higher.
PALI-2108: A Promising Therapeutic Candidate
PALI-2108 is a dual-acting candidate designed to combat inflammation and fibrosis within the gut. Unlike traditional treatments, it specifically targets the lower intestinal region, utilizing a biocompatible approach that maximizes therapeutic benefits while minimizing systemic side effects. Preclinical results have shown promise, highlighting PALI-2108's potential to not only relieve symptoms but also alter the course of the disease itself.
Details of the Phase 1b Study
The upcoming Phase 1b study will include 6-12 participants to comprehensively assess several essential aspects:
- **Safety Monitoring:** Adverse events will be carefully tracked alongside laboratory and EKG assessments.
- **Pharmacokinetics:** The study will examine how PALI-2108 is processed in the body, measuring its levels in blood and specific intestinal tissues.
- **Pharmacodynamics:** The drug's effects will also be analyzed through paired ileal biopsies using cutting-edge RNA sequencing technology, helping to illuminate its mechanisms of action.
- **Exploratory Endpoints:** Additional measures will include patient-reported outcomes and advanced imaging techniques like intestinal ultrasound.
Dosing is projected to initiate in the second half of 2025, with critical readouts expected in early 2026.
Statements from the Leadership
Dr. Mitchell Jones, the Chief Medical Officer at Palisade Bio, expressed excitement about the recent developments, noting that the authorization from Health Canada signifies an important milestone. His insights reflect the company's commitment to pushing beyond mere symptom relief, aiming for a true modification of the disease. The robust clinical profile of PALI-2108 provides hope for patients who have long awaited meaningful options.
Looking Ahead: Commitment to Innovation
Continued development of PALI-2108 will be crucial not only for FSCD but also for supporting upcoming Phase 2 IND applications to the FDA, based on the data retrieved from the ongoing trials. The actionable results from this study will further solidify Palisade's position as a pioneer in treating chronic intestinal diseases.
About Palisade Bio
Palisade Bio dedicates itself to enhancing the treatment landscape for conditions characterized by autoimmune, inflammatory, and fibrotic processes. By employing a targeted, innovative methodology in developing their therapeutics, the company hopes to transform the care of patients battling these challenging diseases.
Frequently Asked Questions
What is Fibrostenotic Crohn’s Disease?
Fibrostenotic Crohn’s disease is a severe complication that can develop in approximately 50% of Crohn's disease patients, leading to intestinal blockages and repeated interventions.
What is PALI-2108?
PALI-2108 is an oral prodrug designed to specifically target and treat inflammation and fibrosis in the gut, showing potential as a first-in-class therapy for FSCD.
When will the dosing begin for the Phase 1b study?
Dosing for the Phase 1b study of PALI-2108 is expected to commence in the second half of 2025.
What outcomes will be measured in this study?
The study will assess safety, pharmacokinetics, pharmacodynamics, and various exploratory endpoints, including patient-reported outcomes.
Who can I contact for more information about Palisade Bio?
For further details, please reach out to the JTC Team at Jenene Thomas via phone at 908-824-0775 or email at PALI@jtcir.com.
